337 related articles for article (PubMed ID: 24685817)
1. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
Werner C; Hoffmann MM; Winkler K; Böhm M; Laufs U
Vascul Pharmacol; 2014 Aug; 62(2):94-102. PubMed ID: 24685817
[TBL] [Abstract][Full Text] [Related]
2. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF
Diabetes Obes Metab; 2015 Nov; 17(11):1042-55. PubMed ID: 26183252
[TBL] [Abstract][Full Text] [Related]
3. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
[TBL] [Abstract][Full Text] [Related]
5. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy.
Raal F; Panz V; Immelman A; Pilcher G
J Am Heart Assoc; 2013 Apr; 2(2):e000028. PubMed ID: 23537802
[TBL] [Abstract][Full Text] [Related]
6. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
[TBL] [Abstract][Full Text] [Related]
7. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
[TBL] [Abstract][Full Text] [Related]
8. The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.
Cai G; Zhang B; Shi G; Weng W; Ma C; Song Y; Zhang J
Lipids Health Dis; 2015 Nov; 14():149. PubMed ID: 26576960
[TBL] [Abstract][Full Text] [Related]
9. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Miyoshi T; Nakamura K; Doi M; Ito H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
[TBL] [Abstract][Full Text] [Related]
10. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
11. Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.
Li JJ; Li S; Zhang Y; Xu RX; Guo YL; Zhu CG; Wu NQ; Qing P; Gao Y; Sun J; Liu G; Dong Q
Medicine (Baltimore); 2015 Dec; 94(52):e2426. PubMed ID: 26717403
[TBL] [Abstract][Full Text] [Related]
12. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
[TBL] [Abstract][Full Text] [Related]
13. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
Hu D; Yang Y; Peng DQ
Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
[TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease.
Li S; Zhang Y; Xu RX; Guo YL; Zhu CG; Wu NQ; Qing P; Liu G; Dong Q; Li JJ
Ann Med; 2015; 47(5):386-93. PubMed ID: 26153823
[TBL] [Abstract][Full Text] [Related]
15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
16. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
Cao G; Qian YW; Kowala MC; Konrad RJ
Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):238-43. PubMed ID: 19075777
[TBL] [Abstract][Full Text] [Related]
17. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
18. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
[TBL] [Abstract][Full Text] [Related]
19. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial.
Awan Z; Seidah NG; MacFadyen JG; Benjannet S; Chasman DI; Ridker PM; Genest J
Clin Chem; 2012 Jan; 58(1):183-9. PubMed ID: 22065156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]